

Corrections

In the article entitled *SCOMP Is Superior to Degenerated Oligonucleotide Primed-Polymerase Chain Reaction for Global Amplification of Minute Amounts of DNA from Microdissected Archival Tissue Samples* (Volume 161, pages 43–51 of the July 2002 issue), the primers listed in Table 2 for D5S500 were incorrect. The correct primer sequences are: 5'-GTATCGGTGAAATGCAACTA-3' and 5'-CTTTTACATTTTGGTACCTTG-3'.

In the article entitled *Abnormal Uterine Bleeding during Progestin-Only Contraception May Result from Free Radical-Induced Alterations in Angiotensin Expression* (Volume 161, pages 979–986 of the September 2002 issue), the grant information was incorrect. The correct grant information is National Institutes of Health grant RO1 HD33937–06.

In the article entitled *Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies* (Volume 163, pages 1021–1031 of the September 2003 issue), Figures 3, 4, and 5 should have appeared in color. The corrected article, including color figures, appears at <http://ajp.amjpathol.org/cgi/content/full/163/3/1021>.

In the article entitled *Expression of Calcium-Binding Proteins MRP8 and MRP14 in Inflammatory Muscle Diseases* (Volume 163, pages 947–956 of the September 2003 issue), the authors' affiliations should have read as follows:

Stephan Seeliger,^{*†} Thomas Vogl,^{*} Ingo Hubert Engels,^{*} J. Michael Schröder,[‡] Clemens Sorg,^{*} Cord Sunderkötter,[§] and Johannes Roth^{*†}

From the Institute of Experimental Dermatology,^{*} the Department of Pediatrics,[†] University of Münster, Münster; the Department of Neuropathology,[‡] University Hospital, RWTH-Aachen, Aachen; and the Department of Dermatology and Allergy,[§] University of Ulm, Ulm, Germany

In the article entitled *Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression* (Volume 163, pages 1013–1020 of the September 2003 issue), the second author's name was incorrectly spelled. The correct spelling for this author's name is Alexander Hergovich.

In the article entitled *Up-Regulation of Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer's Disease* (Volume 163, pages 591–607 of the August 2003 issue), several errors appeared in the print edition. The seventh author's name should have read Inge Grundke-Iqbal. Throughout the article, references to "R134", "134 days" and "R134 days" should have read "R134 days". Other minor errors have also been noted. Please refer to <http://ajp.amjpathol.org/cgi/content/full/163/2/591/DC1> for the corrected pdf of this article.

In the article entitled *Detection of Oncofetal H19 RNA in Rheumatoid Arthritis Synovial Tissue* (Volume 163, pages 901–911 of the September 2003 issue), the last sentence of the third paragraph on page 903 should have read as follows: "Alternatively, the housekeeping gene β -actin (downstream primer: GTGCGACGAAGACGAGACC; upstream primer: CAGAGCCG AGACACCACG; resulting fragment length, 230 bp) was used as an internal standard (conditions: initial denaturation at 93°C for 3 minutes, followed by a total of 28 to 34 cycles; denaturation at 93°C for 45 seconds, annealing at 62°C for 45 seconds, and extension at 72°C for 30 seconds)." In the legend for Figure 5, the symbol § denotes $P < 0.05$ in comparison with RA-SFBs; (§) denotes $P < 0.10$ in comparison with RA-SFBs. In the legend for Figure 6, the symbol + denotes $P < 0.05$ in comparison with the respective stimulus without inhibitor. Additionally in this article, Table 1 appeared incorrectly. The correct table appears here (see Table 1).

Table 1. Clinical Characteristics of the Patients at the Time of Synovectomy/Sampling

| Patients (total) | Gender (m/f) | Age (yrs) | Disease duration (yrs) | RF (+/-) | ESR (mm/1h) | CRP* (mg/l) | # of ARA-criteria (RA) | Concomitant medication | (n) |
|---|--------------|------------|------------------------|------------------|------------------------|-----------------------|------------------------|---|---|
| Rheumatoid arthritis (RA) 26 | 9/17 | 63.2 ± 2.0 | 14.6 ± 2.5 | 24/2 | 45.0 ± 5.3 (n.d.=5) | 25.9 ± 4.0 | 4.9 ± 0.2 | MTX Prednis. Sulfas. Chloroquin Leflunomide NSAIDs | (12) (18) (4) (1) (3) (21) |
| Osteoarthritis 25 | 4/21 | 68.4 ± 1.8 | 4.7 ± 0.5 | 2/19 (n.d.=4) | 18.6 ± 3.9 (n.d.=2) | 4.6 ± 1.1 (n.d.=1) | 0.3 ± 0.1 | Prednis. MTX NSAIDs none | (2) (1) (14) (10) |
| Other arthritides EB32/ReA EB36/ReA | m f | 43 31 | 8 0.13 | + - | 60 50 | 8.5 63.8 | 1 0 | none NSAIDs, Doxycyclin | |
| Joint trauma 7 | 3/4 | 31.9 ± 7.6 | 0.6 ± 0.4 | n.d. | n.d. | n.d. | 0.0 ± 0.0 | L-Thyroxin Nifedipin Propanolol none | (1) (1) (1) (5) |
| Normals 8 | 4/4 | 51.8 ± 6.9 | 0.0 ± 0.0 | n.d. | n.d. | n.d. | 0.0 ± 0.0 | none | (8) |

Abbreviations are defined as follows: m, male; f, female; yrs, years; RF, rheumatoid factor; +/-, positive/negative; ESR, erythrocyte sedimentation rate (mm); CRP, C-reactive protein; *, normal range: < 5 mg/l; ARA, American Rheumatism Association (now American College of Rheumatology); n.d., not determined; RA, rheumatoid arthritis; ReA, reactive arthritis; MTX, Methotrexate; Prednis., Prednisolone; Sulfas., Sulfasalazine; NSAIDs, non-steroidal anti-inflammatory drugs.

For the parameters age, disease duration, ESR, CRP, and # of ARA-Criteria (RA) means ± SEM are given; for the remaining parameters *n* numbers are provided.